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Abstract
Background
The SMART trial is a UK-based, multicentre RCT comparing prophylactic radiotherapy and
symptom-based (deferred) radiotherapy in 203 patients with Malignant Pleural Mesotheli-
oma who had undergone large bore pleural interventions. Using costs and quality of life data
collected alongside the clinical trial, we will estimate the cost-effectiveness of prophylactic
radiotherapy compared to deferred radiotherapy over a 1-year period.
Methods
Healthcare utilization and costs were captured during the trial. Utility weights produced by
the EQ-5D questionnaire were used to determine quality-adjusted life-years (QALY) gained.
The incremental cost-effectiveness ratio was calculated over the one-year trial period.
Results
Costs were similar in the immediate and deferred radiotherapy groups: £5480.40 (SD =
£7040; n = 102) and £5461.40 (SD = £7770; n = 101) respectively. There was also no differ-
ence in QALY: 0.498 (95% CI: [0.45, 0.547]) in the prophylactic radiotherapy group versus
0.525 (95% CI: [0.471, 0.580]) in the deferred group. At a willingness to pay threshold of
£30,000/QALY there was only a 24% chance that prophylactic radiotherapy was cost-effec-
tive compared to deferred radiotherapy.
Conclusions
There was no significant effect of prophylactic radiotherapy on quality of life in the interven-
tion group, nor was there any discernable decrease in healthcare costs. There is little evi-
dence to suggest that prophylactic radiotherapy is a cost-effective intervention in this
population.
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1 Introduction
Malignant pleural mesothelioma is a cancer with a poor prognosis and few treatment options
are available [1]. Patients often need multiple pleural interventions to diagnose and manage
the tumor, which can result in the cancer spreading along the intervention tracts and “Proce-
dure-Tract Metastases” (PTMs) developing [2]. Malignant pleural mesothelioma is sensitive to
radiation therapy in vitro, but its use as radical treatment is precluded by the large doses that
would need to be delivered to the other thoracic structures. However, radiotherapy (RT) can
be safely delivered in smaller, prophylactic doses to intervention sites with minimal side effects
[3, 4] and the efficacy of this has been evaluated in a number of randomised controlled trials
[5–7].
Most recently, the SMART trial was designed to determine whether prophylactic RT would
reduce the rate of PTMs in patients with malignant pleural mesothelioma undergoing large
bore pleural procedures. 203 patients were randomized from 22 UK centres to receive either
prophylactic RT or deferred RT (in the event a PTM developed). After the 12 months follow
up period, 9 patients in the prophylactic RT and 16 patients in the deferred RT groups experi-
enced a PTM (OR of 0.51, 95% CI: [0.19, 1.32], p = 0.14). The trial also showed no improve-
ment in symptoms or quality of life in the prophylactic RT group and hence it was concluded
that prophylactic RT was not an effective treatment in unselected patients with mesothelioma
following pleural instrumentation [8].
Though prophylactic RT was not found to be statistically significant there were fewer PTMs
in the prophylactic group. If the patients from the prophylactic RT group experienced lower
costs then there might be an argument for pursuing further research into prophylactic RT.
Using healthcare utilization and quality of life data that was collected throughout the SMART
trial, we report a detailed analysis of the difference in healthcare costs and quality of life
between the two groups and estimate the cost-effectiveness of prophylactic RT versus deferred
RT in patients with malignant mesothelioma undergoing pleural interventions.
2 Methods
SMART was a multi-centre, open label, phase 3 randomized controlled trial that randomized
203 patients from 22 hospitals in the UK with histocytologically confirmed malignant pleural
mesothelioma who had large-bore pleural interventions in the 35 days prior to recruitment
[8]. Ethical and regulatory approval for the study was obtained from South Central (South-
ampton B) Ethics Committee of the UK National Research Ethics Service before recruitment
commenced (REC number: 11/SC/0408). After written informed consent was obtained,
patients were randomized to immediate (prophylactic) RT within 42 days of pleural interven-
tion or deferred RT. Patients in the deferred group were only given RT after the occurrence of
a PTM (i.e. were treated as usual for this patient population). Information related to the proce-
dures have been described in detail previously [8]. All patients were followed monthly for 1
year by telephone and on a 3-month basis in person at a hospital clinic. The primary outcome
of the trial was the incidence of PTM within 12 months from randomization (defined as a clin-
ically palpable nodule at least 1cm in diameter within 7cm of the margin of the pleural inter-
vention site). Secondary outcomes included chest pain visual analogue scores over 12 months,
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quality of life using the EQ-5D and QLQ-30 questionnaires, survival, adverse events and
healthcare utilization and patient experience.
In this paper we conducted a cost-effectiveness analysis alongside the clinical trial from the
perspective of the healthcare payer, therefore non-medical costs were not included in the anal-
ysis (i.e. patient time and travel costs, costs related to lost productivity, etc.). All patients were
followed for 1 year or until death, whichever occurred first, and the analysis was performed
over this time frame. Median survival was 357 days and 365 days in the immediate and
deferred RT groups respectively, therefore modeling of costs beyond the trial period was not
performed. Given that costs included in the analysis were incurred over the trial follow up
period of up to 1 year, discounting was not performed.
2.1 Healthcare utilization and costs
Healthcare utilization was measured from the perspective of the healthcare payer, the UK
National Health Service (NHS). Healthcare resource utilization was captured in person at
months 1, 3, 6, 9 and 12 and over the telephone for the intervening months. The following
healthcare system utilization variables were captured: A&E visit (manually or by ambulance),
outpatient appointments and profession seen, hospital and ICU stays, radiation, chemother-
apy, thoracic procedures, palliative care and pleural procedures received, along with what anal-
gesia medications were received. Costs were taken from multiple sources, including the NHS
Enhanced Tariff Option [9], the Personal Social Services Research Unit (PSSRU) Unit Costs of
Health and Social Care 2014 [10], and other sources [4, 11]. Table 1 reports the specific costs
for each procedure, and appendix A in S1 File details where each individual cost can be found.
As some cost sources were from different years costs were inflated to 2015 and reported in
2015 UK pounds (£), see appendix A in S1 File for details.
2.2 Utility scores and quality of life
Quality of life in the SMART trial was captured using the European Organization for Research
and Treatment of Cancer Quality-of-Life Questionnaire—Core 30 (QLQ-C30) and the Euro-
Qol-5D (EQ-5D). Patient responses to the EQ-5D were converted to utility scores, ranging
from 0 (death) to 1.0 (perfect health), at each follow up period using the UK valuation set [12].
The EQ-5D survey can describe 243 unique health states, which can be valued in a single utility
score between 0 and 1. In the UK, direct valuation of a subset of 42 health states were obtained
from a sample of 3395 members of the public in 1993 [12]. A linear regression was then used
to predict valuations of all other health states generated by the EQ5D survey. The regression
coefficients for each level of each health state are reported in Appendix B in S1 File. Quality
adjusted life years (QALYs) were determined by combining utility scores derived for each
patient at baseline and each follow-up period (1, 3, 6, 9 and 12 months) using area under the
curve methodology.
For patients with missing baseline utility scores, (4 patients, 98% completion) we imputed
their baseline value using the mean utility score associated with their intervention group. For
patients who survived the 12 months of the trial but missed their last assessment (16 patients,
85% completion) their last valid measurement was carried forward. For patients that withdrew
(4 patients, 98% completion) their last recorded utility score was carried forward to their end
of study (either death or 365 days after entry). If an interval measurement was missed (76
missed total, 97% completion rate) then no imputation is needed. For patients who died their
utility score was set to zero at their date of death and carried forward until the end of study.
Differences in baseline utility scores were controlled for using linear regression methods pro-
posed by Manca, Hawkins and Sculpher [13].
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2.3 Cost effectiveness analysis
To calculate the incremental mean cost and QALY difference between the two groups we used
bootstrapping with 1000 replications to derive an estimate and 95% confidence interval. To
check for potential effects of skewing in the costs we investigated both average and median
cost and QALY per bootstrap sample. To assess the probability that an intervention was cost-
effective at different willingness to pay thresholds for an additional quality adjusted life-year
gained, cost effectiveness acceptability curves (CEACs) were used. Incremental cost-effective-
ness was calculated as the ratio of the difference in costs between the intervention and control
groups divided by the difference in QALYs gained between the groups. Incremental cost-
effectiveness ratios (ICERs) were calculated for the trial period. Given that the ICERs could be
negative (either the intervention was less expensive and more effective, or in contrast, less
effective and more expensive), the ranking of these bootstrap estimates would potentially be
misleading, so 95% confidence intervals were not presented. The use of the CEACs better illus-
trates the uncertainty of the baseline ICER estimate within the context of a funder’s willingness
to pay.
Finally, to supplement the costs investigations we performed a secondary survival analysis
using Kaplan Meier curves and Cox Proportional Hazards regression to evaluate if PTMs were
associated with overall survival.
Table 1. Healthcare utilization and costs summary. See appendix A in S1 File for a detailed description of cost sources.
Prophylactic
Radiotherapy
Deferred
Radiotherapy
Cost Per Unit Prophylactic
Radiotherapy
Deferred
Radiotherapy
n Mean (SD) n Mean (SD) Cost, £ (SD) Cost, £ (SD)
Mean Total Cost per Patient 5480.4 (7039.6) 5461.4 (7770)
Emergency Visit-Ambulance 25 0.2 (0.5) 36 0.4 (0.7) £223 54.7 (110.7) 79.5 (162.6)
Emergency Visit-Other 50 0.5 (0.7) 65 0.6 (1) £170 83.3 (121.4) 109.4 (164.1)
Chemotherapy 111 1.1 (1.2) 140 1.4 (1.2) £300 324.3 (356.1) 413.1 (369.7)
Chemo Dose £119 3.5 (20.2) 8.2 (42.1)
Hospital: >1 Day 73 0.7 (1.1) 79 0.8 (1) £3,204 2293.1 (3503.4) 2506.1 (3317)
Hospital: 1 Day 16 0.2 (0.5) 34 0.3 (0.6) £961 150.7 (443.3) 323.5 (612)
Hospital: Same Day 26 0.3 (1.1) 27 0.3 (0.8) £961 245 (1062.1) 256.9 (802.8)
Days in Hospital 730 7.2 (22.1) 664 6.6 (12.6)
Days in ICU 59 0.6 (3.2) 54 0.5 (4) £904 878.5 (4903.5) 812 (6031.3)
Outpatient: Doctor 446 4.4 (3.5) 467 4.6 (3.6) £60–420 240.4 (235.1) 202.5 (186.5)
Outpatient: Nurse 145 1.4 (2.3) 155 1.5 (2.3) £64 91 (149.5) 98.2 (145.3)
Outpatient: Other 177 1.7 (2.4) 72 0.7 (1.3) £35 60.7 (83.6) 25 (44.1)
Palliative Care 114 1.1 (1.2) 102 1 (1.2) £277 309.6 (331.4) 279.7 (335.8)
Pleural Procedure: Any 15 0.1 (0.5) 38 0.4 (0.9)
Pleural biopsy 1 0 (0.1) 1 0 (0.1) £176 2 (20) 2 (20.1)
Indwelling Pleural Catheter 1 0 (0.1) 3 0 (0.2) £475 5.4 (54.1) 16.2 (93.2)
Diagnostic pleural aspiration 7 0.1 (0.3) 17 0.2 (0.4) £176 13.9 (51.4) 34.1 (90.8)
Chest drain Insertion 2 0 (0.1) 4 0 (0.2) £226 5.1 (36.2) 10.3 (50.9)
Pleurodesis 0 0 (0) 2 0 (0.1) £268 0 (0) 6.1 (43.2)
Therapeutic pleural aspiration 4 0 (0.2) 10 0.1 (0.3) £176 7.9 (39.5) 20 (60.8)
Radiotherapy Received 100 1 (0.4) 11 0.1 (0.3) £277 271.6 (103) 30.2 (86.7)
Cost Per Fraction £92 287.7 (171.1) 45.5 (166.4)
Thoracic Surgery 0 0 (0) 4 0 (0.2) £1,990 0 (0) 78.8 (390.1)
Medication Costs  152.1 (266.7) 104 (182)
https://doi.org/10.1371/journal.pone.0190257.t001
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All analyses were performed in R version 3.2.2 (R Core Team, https://www.R-project.org/).
Significance was set at α = 0.05 for the calculation of 95% confidence intervals and interpreta-
tion of statistical results.
3 Results
Table 2 presents the patient demographics, overall and by treatment group. No difference in
baseline characteristics were seen between groups. Study participants were predominantly
male (89%), with 65% of participants between the ages of 65 and 80.
No significant difference was seen in the overall healthcare utilization or health care costs
between groups (Table 1 contains a summary of the healthcare utilization and healthcare
costs). Mean cost over the trial period was £5480.40 (SD = 7040) in the prophylactic RT group
versus £5461.40 (SD = 7770) in the deferred RT group. Accounting for survival over the 1 year
follow up period, there was no difference in QALYs between groups, with a mean QALY of
0.498 (bootstrapped 95% CI: [0.450, 0.547]) in the prophylactic RT group and a mean QALY
of 0.525 (95% CI: [0.471, 0.580]) in the deferred RT group.
Table 3 presents a summary of the mean costs and quality of life for both groups, stratified
by presence/absence of PTMs. For patients with PTM, mean QALY was slightly higher
and mean costs slightly lower, though the differences were minimal and not statistically
significant.
Table 4 presents a summary of the incremental costs, QALYs and incremental cost-effec-
tiveness ratio (ICER), using both the mean-cost and median-cost per bootstrap sample, while
Fig 1 presents the Cost Effectiveness Plane and CEAC depicting the probability of prophylactic
RT being cost-effective compared to deferred RT at various willingness to pay thresholds. At a
willingness to pay threshold of £30,000/QALY, the probability that prophylactic RT is cost-
Table 2. Patient demographics, disease and treatment information, overall and by intervention group.
Variable Level All (%) Intervention (%) Control (%)
Sex Male 181 (89) 91 (89) 90 (89)
Female 22 (11) 11 (11) 11 (11)
Age <65 38 (19) 21 (21) 17 (17)
65–80 133 (66) 66 (65) 67 (66)
80+ 32 (16) 15 (15) 17 (17)
Length of Follow-up from trial entry to death, withdrawal or 12 months. 12 months 105 (52) 52 (51) 53 (52)
6–11 months 52 (26) 28 (27) 24 (24)
<6 months 46 (23) 22 (22) 24 (24)
Died No 98 (48) 48 (47) 50 (50)
Yes 105 (52) 54 (53) 51 (50)
Type of pleural intervention Large-bore chest drain insertion 3 (1) 1 (1) 2 (2)
Local anaesthetic thoracoscopy 74 (36) 38 (37) 36 (36)
Thoracotomy 9 (4) 3 (3) 6 (6)
Video-assisted thoracoscopic surgery 91 (45) 45 (44) 46 (46)
Indwelling pleural catheter insertion 25 (12) 14 (14) 11 (11)
Other 1 (1) 1 (1) 0 (0)
Mesothelioma histological subtype Epithelioid only 142 (70) 71 (70) 71 (70)
Sarcomatoid 16 (8) 8 (8) 8 (8)
Biphasic (mixed) 37 (18) 19 (19) 18 (18)
Desmoplastic 4 (2) 4 (4) 0 (0)
Other 4 (2) 0 (0) 4 (4)
https://doi.org/10.1371/journal.pone.0190257.t002
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effective compared to deferred RT is 31% using mean-cost analysis and 49% using median-
cost analysis.
Finally, Fig 2 presents the survival curve for the patients, stratified by treatment group and
PTM. A Cox Proportional Hazard regression model was built predicting survival using pres-
ence of a PTM and treatment group. The HR for patients that received deferred RT was 0.96
(95% CI: [0.7, 1.4]) compared to patients receiving the prophylactic RT, while the HR for
patients experiencing a PTM was 0.99 (95% CI: [0.6, 1.8]) compared to patients not experienc-
ing a PTM, suggesting that there was no effect of either the prophylactic RT or of experiencing
a PTM on overall survival.
4 Discussion
Health economic analysis of the SMART trial has shown that from a healthcare payer perspec-
tive, prophylactic RT to pleural intervention sites in Mesothelioma is unlikely to be cost-effec-
tive compared to deferred RT delivered if a PTM develops. No clinically or statistically
significant differences were identified in the mean costs, survival or quality of life of the two
groups. The primary analysis of the SMART trial data [8] also failed to identify a difference in
PTM rate between the treatment groups, concluding that delivery of prophylactic RT to unse-
lected patients with mesothelioma can not be justified.
The concept of delivering prophylactic RT in mesothelioma assumes that it is effective at
reducing PTMs and that its side effects outweigh the symptoms of a PTM. The SMART trial
found that (a) prophylactic RT did not reduce the rate of PTMs significantly, and (b) that
patients in the deferred RT group did not have a significantly lower quality of life. This health
economic analysis has added to these conclusions by demonstrating that (i) there was no dif-
ference in the costs incurred between the two groups, and that (ii) patients that experience a
PTM in either group did not have a noticeably lower quality of life score. If PTMs do not
significantly influence quality of life or survival then it is difficult to justify treating them
Table 3. Summaries of the Quality of Life Years (QALY) and costs, both overall and stratified by the study outcome (occurrence of a procedure tract metastasis, or
PTM).
n Mean SD Median IQR
QALY 203 0.510 0.291 0.510 [0.24, 0.77]
QALY-PTM 25 0.518 0.286 0.594 [0.28, 0.73]
QALY-No PTM 178 0.509 0.293 0.500 [0.24, 0.77]
Costs 203 £5,470.93 £7,393.60 £3,669.93 [£1646.03, £6619.58]
Costs-PTM 25 £4,911.69 £3,392.73 £4,329.46 [£2008.80, £7064.56]
Costs-No PTM 178 £5,549.47 £7,795.85 £3,481.00 [£1546.73, £6493.79]
https://doi.org/10.1371/journal.pone.0190257.t003
Table 4. Summary of the cost-effectiveness analysis, with incremental costs and QALYs, and the resultant ICER.
Mean-Analysis Median Analysis
Average 95% CI Average 95% CI
Prophylactic RT Cost £5,450.29 [£4270.35, £6834.93] £3,082.82 [£2232.58, £4287.22]
Deferred RT Cost £5,453.86 [£4172.01, £7035.46] £3,831.52 [£2303.62, £4790.66]
Cost Difference -£3.57 [£-2100.25, £1934.5] -£748.71 [£-2170.78, £1380.43]
Prophylactic RT QALY 0.498 [0.45, 0.55] 0.496 [0.444, 0.548]
Deferred RT QALY 0.525 [0.47, 0.58] 0.522 [0.468, 0.578]
QALY Difference -0.027 [-0.1, 0.04] -0.02 [-0.095, 0.042]
Incremental Cost-effectiveness ratio £132.04 £28606.46
https://doi.org/10.1371/journal.pone.0190257.t004
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prophylactically, especially when prophylactic treatment does not completely reduce the risk
of experiencing a PTM. Further data from the PIT trial (a UK based RCT evaluating prophy-
lactic irradiation of tracts in mesothelioma) is awaited with interest as this will provide further
efficacy and symptom control data, although no health economic analysis has been planned as
part of this trial [14].
We have demonstrated that there is between a 31%-50% chance of prophylactic RT being
cost effective at £30,000/QALY, the maximum value at which the National Institute of Health
and Care Excellence (NICE) considers an intervention to be cost-effective [15]. As seen in Fig
1, when the willingness to pay increases the cost-effectiveness of prophylactic radiotherapy
decreases. This is because, for most of the bootstrap samples, the prophylactic RT group had a
slight decrease in quality of life overall with no decrease in costs. We would caution against try-
ing to draw conclusions about the difference in quality of life between the prophylactic and
deferred groups, the difference is small and the bootstrapped CI covers 0, suggesting that the
quality of life is roughly the same between the two groups. The difference in median and mean
estimates suggests that the data is slightly long-tailed, but further investigation into these high-
cost patients did not suggest that they were outliers, and since costs incurred appeared to be
relevant to either the disease or the intervention, they were not omitted from the analysis. We
opted to present both the mean and median analysis in the paper as there is some discussion in
the cost-effectiveness literature that both measures can be helpful in cost-effectiveness analysis
interpretation [16]. Given their overall agreement, that the probability that prophylactic RT is
cost effective is low, is helpful in reducing uncertainty about the value for money of the inter-
vention for a decision maker.
Table 3 demonstrates two surprising findings: That patients diagnosed with a PTM had nei-
ther a noticeable drop in quality of life nor an increase in healthcare system costs. Our study
Fig 1. Cost effectiveness plane and CEAC for the intervention. The lines on the cost-effectiveness plane (left) represent willingness-to-pay thresholds of £20,000
(green) and £30,000 (purple). The same willingness to pay thresholds are marked with vertical dotted lines on the CEAC (right). The ellipses represent the area in which
95% of the bootstrap sample values fall.
https://doi.org/10.1371/journal.pone.0190257.g001
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was not sufficiently powered to explain these findings, but for the costs we note that the aver-
age cost for the prophylactic RT group was only about £480 more than the deferred group, and
considering the size and variation of the costs overall in Table 1 the price of treating a PTM is
quite minor. For the lack of difference in quality of life our only hypothesis is that, with a 50%
mortality rate at 1 year, the effect of a PTM may not be as impactful on overall quality of life as
was initially believed. This is not in anyway to suggest that PTMs should not be treated, rather
that the process of diagnosis and treatment of PTM may not be sufficiently taxing on the
patient to warrant prophylactic treatment.
The SMART trial has several strengths. It is a robustly conducted, large randomised con-
trolled trial and is the largest, suitably powered study to evaluate the effects of prophylactic
radiotherapy in mesothelioma. Unlike the previous RCTs in this field the symptoms and qual-
ity of lives of patients in the trial were carefully evaluated, which adds important data regarding
these important patient-centered outcomes to the published literature. To our knowledge, this
is the first time the health economics of prophylactic irradiation of tracts has been evaluated in
this population. This analysis was planned a priori and published with the protocol prior to
data analysis [17].
Fig 2. Kaplan Meier curves for treatment and PTM event. The survival rates for prophylactic treatment patients are presented in red, deferred treatment in blue.
Patients that experienced a PTM are drawn with dashed lines, no-PTM patients with solid lines. At the bottom of the figure the number of patients at risk at each
100-day interval are noted. Some patients go beyond 365 days (study duration) due to the delay in scheduling their final appointment.
https://doi.org/10.1371/journal.pone.0190257.g002
Health economic analysis of the SMART trial
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There are some limitations of our study. The time frame of the study was one year, and
given that close to half the population was still alive at 1 year we may have missed important
health outcomes beyond the scope of the trial. The analysis of a single payer system like the
UK may make the generalizability to other countries more difficult, as the costs incorporated
into our analysis may not be relevant to their systems. We have not included the costs of the
chemotherapy drugs themselves to the analysis due to insufficient data regarding the specific
drugs and doses administered, however the proportion of patients receiving chemotherapy in
the two groups was comparable [8]. This was a secondary analysis of the SMART trial data and
not necessarily powered to detect meaningful differences in healthcare costs.
5 Conclusion
Based on data collected alongside the SMART randomized clinical trial, it is unlikely that
immediate prophylactic RT is cost-effective compared to deferred RT in preventing procedure
tract metastases in patients with malignant mesothelioma undergoing pleural procedures.
There was a no significant effect of prophylactic RT on quality of life in the intervention
group, nor was there any discernable decrease in healthcare costs.
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